Page 2 - Diffuse Scleroderma News Today

The update to 2017 recommendations include targeted synthetic and biologic disease-modifying antirheumatic drugs for the first time.

Despite ILD being a leading cause of death in RA patients, there are no clinical guidelines for monitoring this lung condition in this population, experts say.

Guidelines could tailor cardiovascular risk scores by using a multiplier of 2.5 for systemic sclerosis, 2.0 for lupus, and 1.5 for any other rheumatic disease.

Gender-affirming hormone therapy does not need to be a strict contraindication in transgender patients with rheumatic disease, an author of a new case series and systematic review said.

The Food and Drug Administration has approved a new diagnostic blood test to detect monospecific Ribosomal P antibodies to support a diagnosis of systemic lupus erythematosus.

New and slightly altered session formats break new ground in the first-time hybrid congress, taking place June 1-4 in Copenhagen, Denmark, and virtually.

The search for evidence of inflammatory conditions is difficult, even for experts. One expert explains how this search can be successful.

Nearly all participants in the study showed complete seroconversion, in contrast to similar studies in adults.

In the phase 2 trial, skin biopsies before and after treatment showed significant reductions in inflammatory cytokines relevant to dermatomyositis pathogenesis.

How much do you know about progressive fibrosing interstitial lung disease? Find out with this quick quiz.